Patients with HR‐positive cancer with reported tamoxifen use were less likely to have estradiol and FSH levels in the postmenopausal range as compared to HR‐negative patients (OR = 0.24, 95% CI = 0.15–0.39). Here, BRD2 is linked to cancer.